178312-62-4

Basic information

• Product Name: Homomorpholine hydrochloride
• Synonyms: HOMOMORPHOLINE HYDROCHLORIDE;HOMOMORPHOLINE HCL;Homomorpoline Hydrochloride;Homomorpholinehydrochloride,98%;Albb-008642;1,4-Oxazepine,hexahydro-, hydrochloride (1:1);[1,4]Oxazepane hydrochcloride;Hexahydro-1,4-oxazepine HCl
• CAS NO: 178312-62-4
• Molecular Formula: C5H12ClNO
• Molecular Weight: 137.61
• Mol File: 178312-62-4.mol
• Article Data: 1

Chemical Properties

• Melting Point: 156-154°C
• Boiling Point: 196.9 °C at 760 mmHg
• Flash Point: 72.9 °C
• Appearance: /
• Density: 0.909g/cm3
• Vapor Pressure: 0.328mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• Water Solubility: Slightly soluble in water.
• Sensitive: Hygroscopic
• CAS DataBase Reference: Homomorpholine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Homomorpholine hydrochloride(178312-62-4)
• EPA Substance Registry System: Homomorpholine hydrochloride(178312-62-4)

Safety Data

• Hazard Codes: Xi
• Statements: 10-20/21-34-65-41-37/38
• Safety Statements: 16-26-36/37/39-39
• RIDADR: 2921
• HazardClass: IRRITANT
• Hazardous Substances Data: 178312-62-4(Hazardous Substances Data)

Usage

Description

Homomorpholine hydrochloride is a synthetic intermediate with significant applications in the pharmaceutical industry. It is a derivative of homomorpholine, characterized by its hydrochloride salt form, which contributes to its stability and reactivity in chemical reactions.

Uses

Used in Pharmaceutical Industry:
Homomorpholine hydrochloride is used as a synthetic intermediate for the preparation of homomorpholine oxazolidinone, which possesses potent antibacterial properties. This makes it a valuable compound in the development of new antibiotics to combat resistant bacterial strains.
Additionally, Homomorpholine hydrochloride is used as a key component in the synthesis of A2A adenosine receptor antagonists. These antagonists have therapeutic potential in the treatment of Parkinson's disease, as they can help modulate the neurochemical processes associated with the condition, leading to improved motor function and symptom management in patients.

InChI:InChI=1/C5H11NO.ClH/c1-2-6-3-5-7-4-1;/h6H,1-5H2;1H

Downstream Products

• 1610737-02-4 N-((1s,4s)-4-(2-(4'-((1,4-oxazepan-4-yl)methyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-2-methylthiazole-4-carboxamide trifluoroacetic acid salt 
• 1197291-06-7 tert-butyl (1s,4s)-4-(2-(2'-((1,4-oxazepan-4-yl)methyl)-4'-hydroxybiphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexylcarbamate 
• 1227065-44-2 (4-(3-(1,4-oxazepan-4-yl)pyrazin-2-yloxy)phenyl)(1H-benzo[d]imidazol-2-yl)methanone 
• 1344700-62-4 (2S)-N,2-dimethyl-2-[methyl(4-{[4-(1,4-oxazepan-4-ylmethyl)phenyl]ethynyl}benzoyl)amino]-N'-(tetrahydro-2H-pyran-2-yloxy)propanediamide 
• 1344700-27-1 ethyl 4-{[4-(1,4-oxazepan-4-ylmethyl)phenyl]ethynyl}benzoate 
• 5638-60-8 1,4-oxazepane 

Relevant articles and documents

(Azetidin-1-ylalkyl) lactams as tachykinin antagonists

The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C3 -C7 cycloalkyl, aryl or C1 -C6 alkyl, said C1 -C6 alkyl, said C1 -C6 alkyl being optionally substituted by fluoro, COOH, --COO(C1 -C4 alkyl), C3 -C7 cycloalkyl, adamantyl, aryl or het1, and said C3 -C7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C3 -C7 cycloalkyl, C1 -C4 alkoxy, hydroxy, fluoro, fluoro (C1 -C4) alkyl and fluoro (C1 -C4) Alkoxy; R1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo and trifluormethyl; R2 is --CO2 H, --CONR3 R4, --CONR5 (C3 -C7 cycloalkyl), --NR5 (C2 -C5 alkanoyl), --NR3 R4, --NR5 CONR5 R6, (C3 -C7 cycloalkyl-C1 -C4 alkyl)R5 N--, --NR5 COCF3, --NR5 SO2 CF3, --NR5 (SO2 C1 -C4 alkyl), --NR5 SO2 NR5 R6, --NR5 (SO2 aryl), --N(aryl) (SO2 C1 -C4 alkyl), --OR5, --O(C3 -C7 cycloalkyl), --SO2 NR5 R6, het3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C1 -C4 alkylene; X1 is a direct link or C1 -C6 alkylene; X2 is a direct link, CO, SO2, or NR5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. STR1